SLIDE 1
May 2019 Corporate Presentation
2
The premier commercial partner for late-stage specialty, rare/orphan - - PowerPoint PPT Presentation
The premier commercial partner for late-stage specialty, rare/orphan - - PowerPoint PPT Presentation
The premier commercial partner for late-stage specialty, rare/orphan and hospital products in Europe May 2019 Faster value creation while maintaining strategic flexibility Two sequential service offerings to prepare for and execute launch in
SLIDE 2
SLIDE 3
May 2019 Corporate Presentation
3
We provide excellence in launch preparation and execution
Leadership team consists of senior executives with an average of 27 years
- f experience in Life Sciences industry
Expertise and know-how gathered with over 40 product launches
- n a pan-European level
Achieved multiple successful pan-European and national regulatory approvals Successfully negotiated P&R submissions, incl. HTA submissions, in all European markets Registered dozens of legal entities in Europe and built robust, tax-efficient inter-company structures Hired over 2000 employees for direct EU operations and successfully managed extensive third party distributor networks in and outside the EU
SLIDE 4
May 2019 Corporate Presentation
4
We are experienced in a wide range of disease areas
Neurology (Alzheimer’s disease, MS, Parkinson’s disease) Cardio-vascular diseases Auto-immune (Crohn’s disease, Lupus, rheumatoid arthritis) Infectious diseases Psychiatric disorders (depression, anxiety, schizophrenia) Dermatology (psoriasis) Oncology Pain management Metabolic diseases (diabetes, GH deficiency, hemophilia) Ophthalmology Respiratory diseases (asthma) Rheumatology Neuromuscular disorders Several rare and ultra rare diseases
SLIDE 5
May 2019 Corporate Presentation
5
Go-To-Market Preparation
A single point of contact for all pre-approval activities
Highly experienced European team with expertise in all key areas manages Go-To-Market process through to decision point on direct market entry
- r partnering
Crucial preparatory activities are executed in timely fashion without stretching partner’s global management bandwidth or focus Single point of contact for partner reduces complexity of multiple consultants Services on an as-needed basis, saving the cost of a full but under-utilized Partner European management team Flexible in the event of changes in anticipated regulatory timelines Option to enter into full commercial agreement with Vicarius after the preparatory consulting phase, when organization build-up has to commence
SLIDE 6
May 2019 Corporate Presentation
6
Commercialization
Comprehensive European Commercialization Options
Tailored Contract Sales Organization
Dedicated commercial organizations for our partners on flexible service terms, with option to switch to Dedicated or Portfolio relationship
Dedicated Company Dedicated commercial organizations for assets with exp. peak sales of > €100m and partners interested in building footprint in Europe Multiple, non-competing assets in aligned therapeutic area with exp. peak sales < €100m that do not justify dedicated organization Portfolio Company
SLIDE 7
May 2019 Corporate Presentation
7
Commercializing a first product in Europe by building and managing a Dedicated Company
SLIDE 8
May 2019 Corporate Presentation
8
Partner’s European commercial organization
Vicarius Pharma HQ Dedicated customer-facing Operations (OpCo)
> General management > HR > Regulatory > Market Access > Medical > Supply Chain > Legal > Pharmacovigilance > Compliance > Infrastructure > General management > Business Unit Head > Marketing > MSLs > KAMs > MAMs
Expertise and resources
Dedicated Company
We build dedicated customer-facing operations
SLIDE 9
May 2019 Corporate Presentation
9
Dedicated Company
Increased value capture compared to traditional out-licensing
Vicarius Pharma builds branded European footprint that can be taken over by the partner Partners enjoy goodwill creation and increased brand equity Improved economics through generous royalty stream and profit share Minimum target partner share of ca. 50% of NPV, more on early recovery Strategic options remain open for innovator company as asset can be recovered at any time Valuation of innovator company does not suffer from “poison pill” effect
- f typical out-licensing agreements
SLIDE 10
May 2019 Corporate Presentation
10
Commercializing innovative small/medium size assets through a Portfolio Company
SLIDE 11
May 2019 Corporate Presentation
11
Typical out-license arrangements are not suited for all types of assets:
Some partners (e.g. single asset companies) don’t intend to build a dedicated organization in Europe but want improved economics vs out-licensing and wish to preserve strategic control following launch Assets in highly specialized disease areas may not provide sufficient business opportunity to justify a dedicated organization
Costly executive management and senior expert functions (e.g. VP Medical) Relatively small customer facing organization (KAMs, MSLs) compared to management and expert function overhead
Portfolio Company
Improved economics through leverage
Vicarius Pharma offers an alternative – the Portfolio Company
SLIDE 12
May 2019 Corporate Presentation
12
Portfolio Company
Features and benefits
Portfolio Company commercializes several non-competing assets in same therapeutic area which would be too small to justify single-asset Dedicated Company, or where partner is not interested in building an European Organization Vicarius offers partners opportunity to obtain attractive economic terms plus strategic flexibility to recover asset at any time, e.g. on change of control Recovery right removes poison pill effect of standard out-licenses Minimum target partner share of ca. 50% of NPV, more on early recovery
SLIDE 13
May 2019 Corporate Presentation
13
Why entering Europe with Vicarius is a highly attractive option:
SLIDE 14
May 2019 Corporate Presentation
14
Key benefits of a partnership with Vicarius Pharma
Expert launch preparation and execution Pan-European, right-sized commercial coverage Attractive economics Assured compliance Strategic and structural flexibility
SLIDE 15
May 2019 Corporate Presentation
15
Faster value creation while maintaining strategic flexibility
benefit from our unmatched experience & focused execution reduce the risks of entering Europe and achieve increased value capture retain the highest strategic flexibility Preparing to register and commercialize a first product in Europe with Vicarius Pharma, our partners
SLIDE 16